Suven Life Sciences has shot into the limelight after a lackluster opening. Opening a tad higher by less than Re.1, the stock shot up to Rs.259 and is currently up around 3% at Rs.256 levels. Volumes though remain muted.

The company announced today morning that it has secured two product patents, one each in USA and New Zealand. This patent is for its new chemical entity (NCE) for CNS therapy through new mechanism of action. The USA patent is valid till 2030 and the New Zealand patent is valid till 2031.

The company has said that the granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.

With these new patents, Suven has a total of 20 granted patents from USA and 23 granted patents from New Zealand. These patents are exclusive intellectual property of Suven.